{"schema_version":"secwatch.filing_event.v1","accession":"0001965040-24-000041","form_type":"8-K","ticker":"FTRE","cik":"0001965040","company_name":"Fortrea Holdings Inc.","filed_at":"2024-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.329636+00:00","generated_at":"2026-06-01T06:37:40.391549+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fortrea completes divestiture of Endpoint Clinical and Patient Access to Arsenal for $295M plus $45M milestone","bullets":["Final purchase price $295M paid at closing plus $45M upon achieving transition milestones.","Net proceeds to be used to reduce a portion of Fortrea's overall debt.","Sam Osman appointed CEO of the new entities; Ray Hill named chairman.","Fortrea becomes a pure-play clinical CRO after the divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001965040-24-000041","json":"https://secwatch.observer/filing/0001965040-24-000041.json","markdown":"https://secwatch.observer/filing/0001965040-24-000041.md","text":"https://secwatch.observer/filing/0001965040-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1965040/000196504024000041/0001965040-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1965040/000196504024000041/ftre-20240603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:37:40.391549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}